Public acceptance of peramivir during the 2009 H1N1 influenza pandemic: Implications for other drugs or vaccines under emergency use authorizations

Disaster Medicine and Public Health Preparedness

Volumn 9, Issue 2, 2015, Pages 166-174

  Quinn, Sandra Crouse ^a   Hilyard, Karen ^b   Castaneda Angarita, Nestor ^c   Freimuth, Vicki S ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

communication; public health; vaccines

Indexed keywords

CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; PERAMIVIR;

EMERGENCY TREATMENT; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PATIENT ATTITUDE; PSYCHOLOGY; QUESTIONNAIRE; UTILIZATION;

CYCLOPENTANES; EMERGENCY TREATMENT; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; PATIENT ACCEPTANCE OF HEALTH CARE; SURVEYS AND QUESTIONNAIRES;

EID: 84928570018     PISSN: 19357893     EISSN: 1938744X     Source Type: Journal    
DOI: 10.1017/dmp.2014.156     Document Type: Review

References (24)

1. CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009-March 13, 2010. Centers for Disease Control and Prevention website. http://www.cdc.gov/h1n1flu/estimates/April-March-13.htm. Accessed May 28, 2013.
2. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-1944.
3. Kwan-Gett TS, Baer A, Duchin JS. Spring 2009. H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prep. 2009;3(S2):S109-S116.
4. Centers for Disease Control and Prevention. 2009. Pandemic Influenza A (H1N1) Virus Infections-Chicago, Illinois, April-July 2009. Morbid Mortal Wkly Rep. 2009;58(33):913-918.
5. Chitnis AS, Truelove SA, Druckenmiller JK, et al. Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009 H1N1 influenza A virus infections, April to August 2009. WMJ. 2010;109(4):201.
6. Loganathan R, Sitnitskaya Y, Schori M, et al. Urban Inner-City Minority New Yorkers Hospitalized with Novel Swine-Origin Influenza A H1N1 Virus Illness During the Pandemic of April-June 2009. Internet J Emerg Intensive Care Med. 2010;12(1). http://ispub.com/IJEICM/12/1/7091. Accessed March 2, 2011.
7. Dee DL, Bensyl DM, Gindler J, et al. Racial and ethnic disparities in hospitalizations and deaths associated with 2009 pandemic influenza A (H1N1) virus infections in the United States. Ann Epidemiol. 2011; 21(8):623-630.
8. Interim Questions and Answers about Emergency Use Authorization. Centers for Disease Control and Prevention website. http://www.cdc.gov/h1n1flu/eua/. Accessed June 4, 2010.
9. Quinn SC, Kumar S, Freimuth VS, et al. Public willingness to take a vaccine or drug under Emergency Use Authorization during the 2009 H1N1 pandemic. Biosecur Bioterror. 2009;7(3):275-290.
10. Guidance Emergency Use Authorization of Medical Products. US Food and Drug Administration (FDA) website. 2007. http://www.fda.gov/RegulatoryInformation/Guidances/ucm125127.htm. Accessed May 28, 2013.
11. Nightingale SL, Prasher JM, Simonson S. Emergency Use Authorization (EUA) to enable use of needed products in civilian and military emergencies, United States. Emerg Infect Dis. 2007;13(7):1046-1051.
12. Courtney B. FDA Emergency Use Authorizations (EUAs): What are they and what do they mean for the H1N1 swine flu response? Biosecur Bioterror. 2009;7(2):211-213.
13. Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices. Centers for Disease Control and Prevention website. http://www.cdc.gov/h1n1flu/eua/. Accessed May 28, 2013.
14. Emergency use authorization of Peramivir fact sheet for patients and parents/caregivers. US Food and Drug Administration (FDA) website. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/UCM187799.pdf. Accessed May 28, 2013.
15. FDA-issued Peramivir EUA letter. Centers for Disease Control and Prevention website. http://www.cdc.gov/h1n1flu/eua/EUA%20Peramivir %20Letter%20-%20Frieden.pdf. Accessed May 28, 2013.
16. Birnkrant D, Cox E. The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza. N Engl J Med. 2009;361(23): 2204-2207.
17. Centers for Disease Control and Prevention. Influenza vaccination coverage-United States, 2000-2010. Morb Mortal Wkly Rep. 2011;60: 38-41.
18. Quinn SC, Parmer J, Freimuth V, et al. Exploring Communication, Trust in Government and Vaccine Intention Later in the 2009 H1N1 Pandemic: Results of a National Survey. Biosecur Bioterror. 2013;11(2):96-106.
19. Advancing Regulatory Science at FDA: A Strategic Plan. US Food and Drug Administration website. 2011. http://www.fda.gov/downloads/scienceresearch/specialtopics/regulatoryscience/ucm268225.pdf. Accessed November 29, 2012.
20. Vaughan E, Tinker T. Effective health risk communication about pandemic influenza for vulnerable populations. Am J Public Health. 2009;99(S2):S324-S332. doi: 10.2105/AJPH.2009.162537.
21. Plain Writing Act of 2010. Government Printing Office (GPO) website. http://www.plainlanguage.gov/plLaw/. Accessed December 16, 2013.
22. Freimuth VS, Quinn SC, Thomas SB, et al. African Americans views on research and the Tuskegee Syphilis Study. Soc Sci Med. 2001;52(5):797-808.
23. George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2014;104(2):e16-e31.
24. Questions and Answers for Hospitals and Healthcare Professionals Regarding Termination of the Emergency Use Authorization for Peramivir IV. US Food and Drug Administration website. June 22, 2010. http://www.cdc.gov/H1N1flu/EUA/pdf/Peramivir-Attachment-22Jun2010.pdf. Accessed May 28, 2013.